News and Announcements
Kazia Therapeutics Limited (ASX: KZA) releases September investor newsletter
- Published September 25, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide its latest investor newsletter.
Key topics in this newsletter include:
- An update on activity since the last newsletter was released in June 2019
- An overview of the ANZ Leadership Forum awards, where Kazia was proud to be named a winner
- Details of the six clinical trials we are currently involved in
- A research update on GDC-0084 used in combination with arsenic trioxide
- Details of a poster presented at AACR summarizing data from Part A of our Cantrixil Phase I trial
- Details of a poster presented at EANO outlining the ongoing Phase II study of GDC0084 in glioblastoma
- Information on progress being made in DIPG following on from the work performed by Professor Matt Dun
- Some novel analytical methods used by St Jude Children’s Research Hospital to measure concentration of GDC-0084 in biological samples The newsletter also provides a summary of recent and coming events.
Investors can access the newsletter via the Kazia Therapeutics website at the following link: https://www.kaziatherapeutics.com/mediacentre/insight/september-2019-shareholder-newsletter
For more information on Kazia register your interest below.
Company Updates
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
